Skip Navigation

QJM 2005 98(1):29-34; doi:10.1093/qjmed/hci005
This Article
Right arrow Full Text Freely available
Right arrow FREE Full Text (PDF) Freely available
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Similar articles in ISI Web of Science
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Add to My Personal Archive
Right arrow Download to citation manager
Right arrow Search for citing articles in:
ISI Web of Science (11)
Right arrowRequest Permissions
Right arrow Disclaimer
Google Scholar
Right arrow Articles by Kochar, D.K.
Right arrow Articles by Rawat, N.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Kochar, D.K.
Right arrow Articles by Rawat, N.
Social Bookmarking
 Add to CiteULike   Add to Connotea   Add to Del.icio.us  
What's this?

QJM vol. 98 no. 1 © Association of Physicians 2005; all rights reserved.

Divalproex sodium in the management of post-herpetic neuralgia: a randomized double-blind placebo-controlled study

D.K. Kochar, P. Garg, R.A. Bumb, S.K. Kochar, R.D. Mehta, R. Beniwal and N. Rawat

Received 31 March 2004 and in revised form 30 September 2004

Background: Post-herpetic neuralgia is difficult to treat. Divalproex sodium (valproic acid and sodium valproate in molar ratio 1:1) has been used successfully in the management of various painful neuropathies.

Aim: To study the effectiveness and safety of divalproex sodium in the management of post-herpetic neuralgia.

Design: Randomized double-blind placebo-controlled trial.

Methods: We enrolled 48 consecutively attending out-patients with post-herpetic neuralgia, out of whom three were excluded (two had insufficient pain, one withdrew consent). Quantification of pain was by Short Form-McGill pain questionnaire (SF-MPQ), visual analogue scale (VAS), present pain intensity score (PPI) and 11 point Likert scale (11 PLS) at the beginning of the study, after 2 weeks, 4 weeks and at the end of the study (8 weeks). We also assessed patients' global impression of change by questionnaire at the end of the study.

Results: After 8 weeks treatment with 1000 mg/day divalproex sodium, there was significant reduction in pain: SF-MPQ, 20.47 ± 2.29 to 11.90 ± 6.52 (p < 0.0001); PPI 4.0 ± 0.52 to 1.95 ± 1.29 (p < 0.0001); VAS 70.17 ± 9.21 to 31.27 ± 29.74 (p < 0.0001) and 11 PLS 6.97 ± 0.73 to 3.63 ± 2.34 (p < 0.0001) in comparison to placebo (means ± SEM). The ‘global impression of change’ questionnaire showed much or moderate improvement in pain in 58.2% of patients receiving divalproex vs. 14.8% of those receiving placebo. The drug was well tolerated by all patients, except one who developed severe vertigo after 10 days of treatment.

Discussion: Divalproex sodium provides significant pain relief in patients of post-herpetic neuralgia, with very little incidence of adverse reactions. These data provide a basis for longer trials in a larger group of patients.

Address correspondence to Professor D.K. Kochar, C-54, Sadul Ganj, Bikaner (Raj) 334003, India. e-mail: drdkkochar{at}indiatimes.com


Add to CiteULike CiteULike   Add to Connotea Connotea   Add to Del.icio.us Del.icio.us    What's this?


This article has been cited by other articles:


Home page
JAOA: Journal of the American Osteopathic AssociationHome page
K. E. Galluzzi
Managing Neuropathic Pain
J Am Osteopath Assoc, November 1, 2007; 107(suppl_6): ES39 - ES48.
[Abstract] [Full Text] [PDF]


Home page
JAOA: Journal of the American Osteopathic AssociationHome page
K. E. Galluzzi
Management of Neuropathic Pain
J Am Osteopath Assoc, September 1, 2005; 105(suppl_4): S12 - S19.
[Abstract] [Full Text] [PDF]



Disclaimer: Please note that abstracts for content published before 1996 were created through digital scanning and may therefore not exactly replicate the text of the original print issues. All efforts have been made to ensure accuracy, but the Publisher will not be held responsible for any remaining inaccuracies. If you require any further clarification, please contact our Customer Services Department.